Clinical experience and choice of drug therapy for human immunodeficiency virus disease [see comments]

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Clinical experience and choice of drug therapy for human immunodeficiency virus disease [see comments]

Clin Infect Dis. 1999 Jan;28(1):14-22. Unique Identifier : AIDSLINE MED/99152389
Brosgart CL; Mitchell TF; Coleman RL; Dyner T; Stephenson KE; Abrams DI; Community Consortium, University of California San Francisco AIDS; Program, San Francisco General Hospital, USA.

Abstract: To determine if providers experienced in the management of human immunodeficiency virus (HIV) disease preferred different treatment regimens than providers with less experience, we analyzed data from a national survey of primary care providers' preferred regimens for the management of 30 HIV-related medical conditions. We mailed questionnaires to 999 correct addresses of providers in > 20 cities in the United States in May 1996. We received 524 responses (response rate, 52%). We found a statistically significant association between the number of HIV-infected patients cared for by the provider and the likelihood that the provider would report prescribing highly active antiretroviral therapy and multidrug combinations for treatment of opportunistic infections. Providers with few HIV-infected patients were substantially less likely to report using new therapeutic regimens or new diagnostic tools. We concluded that the preferred regimens of experienced providers are more likely to be consistent with the latest information on treatment for HIV disease than are those of less experienced providers.

Keywords: JOURNAL ARTICLE Anti-HIV Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*DRUG THERAPY/PREVENTION & CONTROL Drug Therapy, Combination Family Practice Health Care Surveys Human HIV Infections/COMPLICATIONS/*DRUG THERAPY *Physician's Practice Patterns *Primary Health Care
Comment in: Clin Infect Dis 1999 Jan;28(1):23-5
990930
A9991302

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .